India, May 6 -- Bayer AG (BYR.L,BAYRY.PK,BAYZF.PK,BAY.MI,BAYN.DE), a German healthcare and agriculture conglomerate, on Wednesday, announced that it has agreed to acquire Perfuse Therapeutics Inc. for up to $2.45 billion to expand its ophthalmology pipeline.
The transaction includes an upfront payment of $300 million, along with additional development, regulatory, and commercial milestone payments.
The acquisition will give Bayer full rights to PER-001, a Phase II small molecule endothelin receptor antagonist being developed for the treatment of glaucoma and diabetic retinopathy.
The deal is subject to regulatory approvals and approval from Perfuse's stockholders.
googletag.cmd.push(function() { googletag.display('div-gpt-ad-15681895098...